Emerging therapies for acute ischemic stroke: new therapies on trial.

Abstract

HomeStrokeVol. 34, No. 2Emerging Therapies for Acute Ischemic Stroke Free AccessReview ArticlePDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessReview ArticlePDF/EPUBEmerging Therapies for Acute Ischemic StrokeNew Therapies on Trial Marc Fisher, MD and Thomas G. Brott, MD Marc FisherMarc Fisher From the Department of Neurology, University of Massachusetts Medical School, Worcester, Mass (M.F.), and the Department of Neurology, Mayo Medical School, Jacksonville, Fla (T.G.B.). Search for more papers by this author and Thomas G. BrottThomas G. Brott From the Department of Neurology, University of Massachusetts Medical School, Worcester, Mass (M.F.), and the Department of Neurology, Mayo Medical School, Jacksonville, Fla (T.G.B.). Search for more papers by this author Originally published1 Feb 2003https://doi.org/10.1161/01.STR.0000054627.69159.C2Stroke. 2003;34:359–361The development of additional effective therapies for acute ischemic stroke remains a challenging but critical endeavor. Intravenous recombinant tissue plasminogen activator (rtPA) initiated within 3 hours of stroke onset remains the only approved and validated therapy for acute ischemic stroke, and regulatory approval has expanded recently. Many other therapies have been evaluated, and these trials have either been inconclusive or negative.1 These acute stroke trials do provide valuable information concerning how to implement future trials and some glimmers of hope about existing data. Some of the lessons learned from prior acute stroke trials that will help to guide future trials are outlined below. The two fundamental approaches to the development of acute stroke therapy remain reperfusion and neuroprotection. This short review will focus on the current status of both approaches and how they might be combined, hopefully in the near future.Negative acute stroke treatment trials may be explained by the following: The agents evaluated in clinical trials may not have been adequately tested in preclinical studies to provide robust confirmation of efficacy in appropriate animal models.Side effects precluded adequate drug assessment or did not allow use of adequate drug concentrations.Because of macro-occlusions and, perhaps, micro-occlusions, the drug did not penetrate into or beyond the penumbral tissue in adequate concentrations.Trials included patients not appropriate for the purported mechanism of action of the drug being tested.Patients were included too late after stoke onset to allow for adequate assessment of the drug’s efficacy, and imaging studies were not done to identify patients with appropriate tissue for treatment.Trials have been inadequately powered to detect modest treatment effects.Trials included too many patients with mild or very severe deficits in whom treatment effects are likely difficult to assess with currently used outcome measures.The single primary outcome measure chosen to assess drug efficacy may not be sensitive enough to detect modest treatment effects.Currently, intravenous rtPA within 3 hours of stroke onset is used in only a very small percentage of acute ischemic stroke patients at most centers,2 although in a few locations, 5% to 10% of such patients receive this intervention.3 From published reports, the efficacy and safety of intravenous rtPA when used in routine clinical practice seems to be comparable to that reported in controlled clinical trials.4 An important challenge remains how to increase the percentage of patients treated within the 3-hour window. This will require additional physician and patient educational efforts, as well as enhancement of healthcare delivery systems.5 Not only does the percentage of patients treated with intravenous rtPA needs to be maximized within 3 hours from stroke onset, it is also critical that physicians try to initiate treatment as soon as possible and not wait until the end of 3-hour window. A reanalysis of the National Institute of Neurological Disorders and Stroke (NINDS) rtPA study data confirmed that treatment earlier in the 3-hour window is clearly more beneficial than treatment later.6 A combined analysis of the NINDS, European Cooperative Acute Stroke Study (ECASS), and Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke (ATLANTIS) trials emphasized this point.7 This combined analysis demonstrated that patients treated within 90 minutes of stroke onset had an odds ratio of 2.83 (95% confidence interval, 1.77 to 4.53) of achieving a modified Rankin outcome of 0 to 1, whereas patients treated from 91 to 180 minutes had an odds ratio of 1.53 (95% CI, 1.11 to 2.11). Interestingly, even patients treated from 181 to 270 minutes from stroke onset were shown to benefit from intravenous rtPA (odds ratio, 1.40; 95% confidence interval, 1.06 to 1.85). It is clear, however, that the absolute benefit with intravenous rtPA initiated beyond 90 minutes is relatively modest, with an absolute treatment effect of 5% to 6% and a number needed to treat for one beneficial outcome approaching 20.Additional goals for the expanded use of thrombolysis in acute stroke will be to establish reperfusion more rapidly and to extend the therapeutic time window for effective reperfusion therapy. Several approaches to result in more rapid reperfusion are under investigation. One approach is to use endovascular methodologies such as mechanical clot retrieval devices, devices to dissolve rapidly and suction intravascular clots, and intra-arterial ultrasound devices in conjunction with intra-arterial thrombolysis.8 Another approach under preliminary investigation is to combine transcranial ultrasound with intravenous rtPA, because preliminary data suggest that this combination may lead to more rapid reperfusion.9 Combining initial intravenous rtPA with intra-arterial rtPA given later is also being investigated to determine if delayed intra-arterial therapy after initial lower-dose intravenous rtPA can be used safely and effectively if the initial intravenous therapy does not induce successful reperfusion.10 Enhancing reperfusion by combining intravenous or intra-arterial thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor abciximab is also under study. The rationale is that platelet activation may be enhanced by plasminogen activators, but platelet aggregation, which is critical for clot formation, can be effectively inhibited by blocking the IIb/IIIa receptor. Abciximab, a long-acting IIb/IIIa inhibitor, was investigated in preliminary studies primarily focused on safety in combination with intravenous reteplase.11 Eptifibatide, a shorter acting agent, has been studied in combination with intra-arterial thrombolysis,12 and a dose-escalation study of eptifibatide and low-dose intravenous rtPA is underway (A. Pancioli, MD, unpublished data, 2002). Interestingly, abciximab has also been studied alone in acute ischemic stroke. Two safety studies demonstrated a reasonable safety profile, and the second study provided a hint of efficacy.13,14 A larger efficacy trial is apparently being designed.A potentially promising approach to extending the therapeutic time window for both thrombolytic and neuroprotective drugs is the use of imaging techniques to identify patients with potentially salvageable ischemic tissue hours after stroke onset. Currently, diffusion-perfusion MRI is the imaging technology most widely employed for identifying potentially salvageable ischemic tissue.15 Early after stroke onset, the volume of the perfusion MRI (PWI) abnormality depicting reduced perfusion in the brain’s microvasculature is typically substantially larger than the region of diffusion MRI (DWI) abnormality, which depicts ischemic brain regions of high energy metabolism failure where ion homeostasis has been lost. The region of PWI abnormality with a normal DWI is termed the diffusion-perfusion mismatch and seems to provide an approximation of the potentially salvageable ischemic zone, ie, the ischemic penumbra.16 The DWI-PWI mismatch is clearly only an approximation of the ischemic penumbra because some of the abnormal PWI region is only oligemic and will not go onto infarction, and shortly after stroke onset some of the DWI abnormality is potentially reversible. Nevertheless, the presence of a DWI-PWI mismatch in open-label studies seems to identify stroke patients up to 6 hours after onset who are more likely to improve with intravenous rtPA than patients without a mismatch.17 The use of DWI-PWI to identify patients for inclusion/exclusion in intravenous thrombolysis trials has begun. In Australia, the Echo- planar Imaging Thrombolysis Evaluation Trial (EPITHET) is underway to determine if patients with a DWI/PWI mismatch treated with intravenous rtPA 3 to 6 hours after stroke onset have a reduction of final infarct size and improved clinical outcome compared with placebo-treated group.18 The desmetoplase in acute stroke (DIAS) trial is using the presence of a DWI/PWI mismatch up to 9 hours after stroke onset to randomize patients in a Phase II B dose-escalation safety study of bat rtPA (W. Soehngen, MD, unpublished data, 2002). Another imaging modality that may be potentially useful for detecting the presence of potentially salvageable ischemic tissue shortly after stroke onset is perfusion computed tomography. A preliminary study demonstrated that determining cerebral blood flow and cerebral blood volume levels with perfusion computed tomography early after ischemic stroke onset seemed to distinguish potentially salvageable ischemic tissue from tissue already irreversibly damaged.19 This observation will have to be validated in a larger sample size and be related to delayed infarct volume and clinical outcome before clinical trials can be implemented.The development of neuroprotective therapies for acute ischemic stroke is based on the concept of impeding the cascade of ischemic injury induced by focal disruption of blood flow to the brain.20 Animal studies have shown convincingly that neuroprotective drugs given after stroke onset can reduce infarct size and improve functional outcome measures.1 Unfortunately, modeling has not been ideal. Initiation of pharmacotherapy has, in most experiments, not been sufficiently delayed to mimic the clinical setting. Experimental drug administration has often followed early effective reperfusion, which is rare clinically. Penetration and measurement of drug concentrations within the ischemic region have, in most cases, not been measured rigorously. The animal data have not yet been translated into clinical trials demonstrating significant treatment efficacy.Most prior neuroprotection trials had serious flaws that precluded adequate assessment of the drug being studied, and the lessons learned from these trials reflect many of the problems with prior neuroprotection trials. The concept of neuroprotection should not be abandoned, but refined. Monotherapy neuroprotection drug development might be proven to be effective for selected acute ischemic stroke patients. The drugs to be evaluated in clinical trials will need to be rigorously tested in preclinical stroke models designed to investigate dose ranges, time window of treatment effect, histological and functional outcomes, sustained treatment effects, and toxicology.21 Failure to provide evidence of safety, efficacy, and a prolonged treatment effect in animals will likely predict failure in clinical trials. Unfortunately, the converse observation of efficacy in animals may not predict success in patients. Human neuroprotection trials need to be well designed and performed to have a reasonable chance for success. The studies should be adequately powered to detect modest absolute benefits in comparison with placebo, enroll patients as soon as possible after stroke onset, target patients of moderate severity, and use outcome measures with the broadest chance to detect meaningful treatment effects.22 A number of new neuroprotection trials are now underway or will begin shortly. These include studies of the antioxidant, Ebselen, the spin trap agent, NXY-059, magnesium, a noncompetitive NMDA antagonist, the AMPA antagonist, YM872, the serotonin antagonists, Repinotan and SUN N4057, and the astrocyte inhibitor, ONO-2506.23–28 Hopefully, one or more of these drugs or others will demonstrate treatment efficacy.The basic pathophysiology of acute ischemic stroke can be summarized simplistically as localized vascular occlusion inducing a complex array of cellular consequences, leading to irreversible tissue injury and ultimately clinically measurable impairment.29 It is therefore logical to conclude that maximizing therapy will require combinations of different therapies. The benefits of early reperfusion are clear, and combined reperfusion strategies such as the use of intravenous thrombolysis, intra-arterial thrombolysis, mechanical thrombolysis, and platelet glycoprotein IIb/IIIa antagonists to maximize reperfusion are potentially attractive approaches. Combining thrombolysis with neuroprotection to target both the vascular and cellular consequences of focal brain ischemia theoretically should provide greater benefits than either approach alone.30 Neuroprotection initiated before or concomitant with thrombolysis might extend the time window and extent of therapeutic effects of thrombolysis by delaying the evolution of salvageable ischemic tissue toward irreversible injury. Perhaps more importantly, thrombolysis given before or with neuroprotection will likely enhance the delivery of neuroprotective drugs to ischemic brain, presumably enhancing the likelihood of tissue salvage by the neuroprotective drug. Endovascular reperfusion techniques could even allow bypassing occlusions to administer neuroprotective agents. Penetration into and beyond major arterial trunk occlusions with the guide catheter is an initial step in most current intra-arterial protocols. A neuroprotective drug could be injected beyond the occlusion at that time to maximize drug concentrations within the entire ischemic region.31Another potential synergistic effect of thrombolysis and neuroprotection would be the use of neuroprotectants designed to ameliorate reperfusion injury after successful thrombolysis-induced reperfusion. An initial pilot study combining Lubeluzole with rtPA demonstrated the feasibility of combining the intravenous thrombolysis and neuroprotection approach.32 Currently, the AMPA antagonist YM872 is being studied in conjunction with intravenous rtPA initiated within 3 hours of stroke onset.25 Other combination trials combining neuroprotective drugs that affect different components of the ischemic cascade or that combine neuroprotection and/or thrombolysis with manipulation of physiological variables such as temperature need to be considered. The future of acute stroke therapy trials will be to move increasingly in the direction of more sophisticated and complex multimodality trials. The move to multimodality trials will require careful planning and cooperation among industry, investigators, centralized granting agencies, and regulatory bodies.The opinions expressed in this editorial are not necessarily those of the editors or of the American Stroke Association.FootnotesCorrespondence to Marc Fisher, MD, UMASS/Memorial Healthcare, 119 Belmont St, Worcester, MA 01605. E-mail [email protected] References 1 Fisher M, Schabitz WR. An overview of acute stroke therapy. Arch Intern Med. 2000; 160: 3196–4006.CrossrefMedlineGoogle Scholar2 Nilasena DS, Kresowik TF, Wiblin RT, Piskac AF, Kresowik RA, Brenton MA, Wilwert JM, Hendel ME. Assessing patterns of tPA use in acute stroke. Stroke. 2002; 33: 354.Abstract.Google Scholar3 Grotta JC, Burgin S, El-Mitwalli A, Long M, Campbell M, Morgenstern LB, Malkoff M, Alexandrov AV. Intravenous tissue-type plasminogen activator therapy for ischemic stroke. Arch Neurol. 2001; 58: 2009–2013.CrossrefMedlineGoogle Scholar4 Koennecke HC, Nohr R, Leistner S, Marx P. Intravenous tPA for ischemic stroke: team performance over time, safety and efficacy in a single center, 2 year experience. Stroke. 2001; 32: 1074–1078.CrossrefMedlineGoogle Scholar5 Morgenstern LB, Staub L, Chan W, Wein TH, Barthomew LK, King M, Felberg RA, Burgin SW, Groff J, Hickenbottom SL, Saldin K, Demchuk AM, Kalra A, Dhingra A, Grotta JC. Improving delivery of acute stroke therapy: the TLL Temple Foundation Stroke Project. Stroke. 2002; 33: 160–166.CrossrefMedlineGoogle Scholar6 Marler JR, Tilley BC, Lu M, Brott TG, Lyden PL, Grotta JC, Broderick JP, Levine SR, Frankel MP, Horowitz SH, Haley EC, Lewandowsi CA, Kwiatkowski TP. Early stroke treatment is associated with better outcome: the NINDS rt-PA stroke study. Neurology. 2000; 55: 1649–1655.CrossrefMedlineGoogle Scholar7 Brott T, Kaste M, Albers GW. Analysis of the NINDS, ECASS 1 and ECASS 11 and ATLANTIS data sets. Presented at the 27th International Stroke Conference, San Antonio, Texas, February 2002.Google Scholar8 Lutsep HL. Mechanical thrombolysis in acute stroke. EMedicine Neurology. 2001;2. Available at: http://www.emedicine.com/neuro/topic702.htm; Accessed June 2002.Google Scholar9 Alexandrov AV, Demchuk AM, Felberg RA, Christov I, Barber PA. High rate of complete recanalization and dramatic clinical recovery during tPA infusion when continuously monitored with 2 MHz transcranial doppler monitoring. Stroke. 200; 31: 610–614.LinkGoogle Scholar10 Lewandowski CA, Frankel M, Tomsick TA, Broderick J, Frey J, Clark W, Starkman S, Grotta J, Spilker J, Khoury J, Brott T. Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke: Emergency Management of Stroke (EMS) Bridging Trial. Stroke. 1999:2598–2605.MedlineGoogle Scholar11 Quershi AI. A prospective study to assess the safety and efficacy of intra-arterial reteplase and intravenous abciximab in patients with acute ischemic stroke. Presented at the clinical trials session, 27th International Stroke Conference, San Antonio, Texas, February 2002.Google Scholar12 McDonald CT, O’Donnell J, Bemporad J, Greer D, Lee KE, Ougorets I, Rosand J, Buoanno F, Schwamm LH, Rordorf G, Putnam C, Korshetz WJ. The clinical utility of intravenous integrilin combined with inta-arterial tissue plasminogen activator in acute ischemic stroke. Stroke. 2002; 33: 359.Abstract.Google Scholar13 The Abciximab in Ischemic Stroke Investigators. Abciximab in acute ischemic stroke: a randomized, double-blind, placebo-controlled, dose-escalation study: Stroke Investigators. Stroke. 2000; 31: 601–609.CrossrefMedlineGoogle Scholar14 Adams HP, Bogousslavsky J, Cook R, Davalos A, Fazekas F, Hacke W, Hillburn JW, Oemar B, Reid PR, Shuaib A, Torner JC, Troullias. The safety and efficacy of abciximab in acute ischemic stroke. Ann Neurol. 2002; 52: S64.Abstract.CrossrefGoogle Scholar15 Neumann-Haefelin T, Moseley ME, Albers GW. New magnetic resonance imaging methods for cerebrovascular disease: emerging clinical applications. Ann Neurol. 2000; 31: 559–570.Google Scholar16 Schlaug G, Benfield A, Baird AE, Siewert B, Lovblad KO, Parker RA, Edelmann RR, Warach S. The ischemic penumbra: operationally defined by diffusion perfusion MRI. Neurology. 1999; 53: 1528–1537.CrossrefMedlineGoogle Scholar17 Parsons MW, Barber PA, Chalk J, Darby D, Rose S, Desmond PM, Gerrarty RP, Tress BM, Wright PM, Donnan GA, Davis SM. Diffusion and perfusion-weighted MRI response to thrombolysis in stroke. Ann Neurol. 2002; 51: 28–37.CrossrefMedlineGoogle Scholar18 Epithet Investigators. Echoplanar imaging thrombolysis evaluation trial. Presented at the clinical trial session, 27th International Stroke Conference, San Antonio, Texas, February 2002.Google Scholar19 Wintermark M, Bogousslavsky J, Thiren JP, Maeder P, Chalaron M, Schnyder P, Bogousslavsky J, Meuli R. Prognostic accuracy of admission cerebral blood flow measurements by perfusion CT in acute stroke patients. Ann Neurol. 2002; 51: 417–432.CrossrefMedlineGoogle Scholar20 Lee JM, Zipfel GJ, Choi DW. The changing landscape of ischaemic brain injury mechanisms. Nature. 1999; 399: A7–A14.CrossrefMedlineGoogle Scholar21 Stroke Therapy Academic Industry Roundtable. Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke. 1999; 30: 2752–2758.CrossrefMedlineGoogle Scholar22 Frankel MR, Morgenstern LB, Kwiatkowski T, Lu M, Tilley BC, Broderick JP, Libman R, Levine SR, Brott T. Predicting prognosis after stroke. Neurology. 2000; 55: 952–959.CrossrefMedlineGoogle Scholar23 Yamaguchi T, Sano K, Takakura K, Saito I, Shinohara Y, Asano T, Yasuhara H. Ebselen in acute ischemic stroke: a placebo controlled, double-blind study. Stroke. 1998; 29: 12–17.CrossrefMedlineGoogle Scholar24 Lees KR, Sharma AK, Barer D, Ford GA, Kostulas V, Cheng YF, Odergren T. Tolerability and pharmacokinetics of the nitrone NXY-059 in patients with acute stroke. Stroke. 2001; 32: 675–680.CrossrefMedlineGoogle Scholar25 Muir K, Lees KR. A randomized, double-blind, placebo-controlled pilot trial of intravenous magnesium sulfate in acute stroke. Stroke. 1995; 26: 1183–1188.CrossrefMedlineGoogle Scholar26 Peterson C, Prince HC, Williams B, Tempel D, Grotta JC. ARTIST+: AMPA receptor treatment is ischemic stroke trial, YM872+alteplase. Presented at the clinical trials session, 27th International Stroke Conference, San Antonio, Texas, February 2002.Google Scholar27 Safety, efficacy and tolerability of repinotan in patients with acute ischemic stroke. Available at: ClinicalTrials.gov. Accessed November 2002.Google Scholar28 A study to evaluate the effects of ONO-2506 intravenous infusion in patients with acute ischemic stroke. Accessed at: Clinical Trials. gov.Google Scholar29 Fisher M. Characterizing the target of acute stroke treatment. Stroke. 1997; 28: 866–872.CrossrefMedlineGoogle Scholar30 Yang Y, Li Q, Miyashita H, Howlett W, Siddiqui M, Shuaib A. Usefulness of postischemic thrombolysis with or without neuroprotection in a focal embolic model of cerebral ischemia. J Neurosurg. 2000; 92: 841–847.CrossrefMedlineGoogle Scholar31 Meschia JF, Brott TG. New insights on thrombolytic treatment of acute ischemic stroke. Curr Neurol Neurosci Rep. 2001; 1: 19–25.CrossrefMedlineGoogle Scholar32 Grotta J, The Combination Therapy Stroke Trial Investigators. Combination therapy stroke trial: recombinant tissue-type plasminogen activator with/without lubeluzole. Cerebrovasc Dis. 2001; 12: 258–263.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Milani D, Cross J, Anderton R, Blacker D, Knuckey N and Meloni B (2017) Delayed 2-h post-stroke administration of R18 and NA-1 (TAT-NR2B9c) peptides after permanent and/or transient middle cerebral artery occlusion in the rat, Brain Research Bulletin, 10.1016/j.brainresbull.2017.09.012, 135, (62-68), Online publication date: 1-Oct-2017. Politidis R, Lyang O and Kochetov A (2016) The markers of development of aggregation aspirin resistance in patients with coronary heart disease, Laboratornaya sluzhba, 10.17116/labs20165237-41, 5:2, (37), . Lin Y, Xu M, Wan J, Wen S, Sun J, Zhao H and Lou M (2015) Docosahexaenoic acid attenuates hyperglycemia-enhanced hemorrhagic transformation after transient focal cerebral ischemia in rats, Neuroscience, 10.1016/j.neuroscience.2015.06.024, 301, (471-479), Online publication date: 1-Aug-2015. Almaliti J, Nada S, Carter B, Shah Z and Tillekeratne L (2013) Natural products inspired synthesis of neuroprotective agents against H2O2-induced cell death, Bioorganic & Medicinal Chemistry Letters, 10.1016/j.bmcl.2013.01.013, 23:5, (1232-1237), Online publication date: 1-Mar-2013. Wang Y, MA T, Zhou L, Li M, Sun X, Wang Y and Gu S (2013) Penehyclidine hydrochloride protects against oxygen and glucose deprivation injury by modulating amino acid neurotransmitters release, Neurological Research, 10.1179/1743132813Y.0000000247, 35:10, (1022-1028), Online publication date: 1-Dec-2013. An Y, Zhao Z, Sheng Y, Min Y and Xia Y (2011) Therapeutic time window of YGY-E neuroprotection of cerebral ischemic injury in rats, Drug Discoveries & Therapeutics, 10.5582/ddt.2011.v5.2.76, 5:2, (76-83), . Wang Y, Ma T, Li M, Sun X, Wang Y and Gu S (2011) Regulated Hypoxia/Reperfusion-Dependent Modulation of ERK1/2, cPLA 2 , and Bcl-2/Bax : A Potential Mechanism of Neuroprotective Effect of Penehyclidine Hydrochloride , International Journal of Neuroscience, 10.3109/00207454.2011.570611, 121:8, (442-449), Online publication date: 20-Jul-2011. Rathbone M, Saleh T, Connell B, Chang R, Su C, Worley B, Kim M and Jiang S (2011) Systemic administration of guanosine promotes functional and histological improvement following an ischemic stroke in rats, Brain Research, 10.1016/j.brainres.2011.06.027, 1407, (79-89), Online publication date: 1-Aug-2011. McEwen B and Paterson P (2010) Caloric restriction provided after global ischemia does not reduce hippocampal cornu ammonis injury or improve functional recovery, Neuroscience, 10.1016/j.neuroscience.2009.11.076, 166:1, (263-270), Online publication date: 1-Mar-2010. Matošević B, Zangerle A, Furtner M, Knoflach M, Werner P, Prantl B, Wille G, Illmer A, Mair A, Spiegel M, Schmidauer C, Sojer M, Muigg A, Willeit J and Kiechl S (2009) Einsatz der Thrombolyse beim akut ischämischen SchlaganfallImplementation of thrombolysis in acute stroke – 10-year results of the Innsbruck stroke registry, Wiener klinische Wochenschrift, 10.1007/s00508-009-1201-z, 121:23-24, (750-756), Online publication date: 1-Dec-2009. Zhao H (2009) Ischemic Postconditioning as a Novel Avenue to Protect against Brain Injury after Stroke, Journal of Cerebral Blood Flow & Metabolism, 10.1038/jcbfm.2009.13, 29:5, (873-885), Online publication date: 1-May-2009. Szénási G, Vegh M, Szabo G, Kertesz S, Kapus G, Albert M, Greff Z, Ling I, Barkoczy J, Simig G, Spedding M and Harsing L (2008) 2,3-Benzodiazepine-type AMPA receptor antagonists and their neuroprotective effects, Neurochemistry International, 10.1016/j.neuint.2007.07.002, 52:1-2, (166-183), Online publication date: 1-Jan-2008. Ishibashi H and Funakoshi Y (2008) Serum S-100B protein levels in left- and right-hemisphere strokes, Journal of Clinical Neuroscience, 10.1016/j.jocn.2007.01.012, 15:5, (520-525), Online publication date: 1-May-2008. Ishibashi H, Pettigrew L, Funakoshi Y and Hiramatsu M (2013) Pharmacokinetics of Arundic Acid, an Astrocyte Modulating Agent, in Acute Ischemic Stroke, The Journal of Clinical Pharmacology, 10.1177/0091270006299090, 47:4, (445-452), Online publication date: 1-Apr-2007. Dempsey R and Kalluri H (2007) Ischemia-Induced Neurogenesis: Role of Growth Factors, Neurosurgery Clinics of North America, 10.1016/j.nec.2006.10.011, 18:1, (183-190), Online publication date: 1-Jan-2007. Zhao H (2007) The Protective Effect of Ischemic Postconditioning Against Ischemic Injury: From the Heart to the Brain, Journal of Neuroimmune Pharmacology, 10.1007/s11481-007-9089-8, 2:4, (313-318), Online publication date: 30-Oct-2007. Mocco J, Shelton C, Sergot P, Ducruet A, Komotar R, Otten M, Sosunov S, MacArthur R, Kennedy T and Connolly E (2007) O-DESULFATED HEPARIN IMPROVES OUTCOME AFTER RAT CEREBRAL ISCHEMIA/REPERFUSION INJURY, Neurosurgery, 10.1227/01.neu.0000306109.55174.e6, 61:6, (1297-1304), Online publication date: 1-Dec-2007. Duckworth E, Butler T, Collier L, Collier S and Pennypacker K (2006) NF-κB protects neurons from ischemic injury after middle cerebral artery occlusion in mice, Brain Research, 10.1016/j.brainres.2006.02.103, 1088:1, (167-175), Online publication date: 1-May-2006. Adibhatla R, Hatcher J and Dempsey R (2006) Lipids and lipidomics in brain injury and diseases, The AAPS Journal, 10.1007/BF02854902, 8:2, (E314-E321), Online publication date: 1-Jun-2006. Tatro J (2006) Melanocortins Defend their Territory: Multifaceted Neuroprotection in Cerebral Ischemia, Endocrinology, 10.1210/en.2005-1573, 147:3, (1122-1125), Online publication date: 1-Mar-2006. Mezzapesa D, Petruzzellis M, Lucivero V, Prontera M, Tinelli A, Sancilio M, Carella A and Federico F (2006) Multimodal MR examination in acute ischemic stroke, Neuroradiology, 10.1007/s00234-005-0045-0, 48:4, (238-246), Online publication date: 1-Apr-2006. Wang J, Portbury S, Thomas M, Barney S, Ricca D, Morris D, Warner D and Lo D (2006) Cardiac glycosides provide neuroprotection against ischemic stroke: Discovery by a brain slice-based compound screening platform, Proceedings of the National Academy of Sciences, 10.1073/pnas.0600930103, 103:27, (10461-10466), Online publication date: 5-Jul-2006. Matucz É, Móricz K, Gigler G, Benedek A, Barkóczy J, Lévay G, Hársing L and Szénási G (2006) Therapeutic time window of neuroprotection by non-competitive AMPA antagonists in transient and permanent focal cerebral ischemia in rats, Brain Research, 10.1016/j.brainres.2006.09.043, 1123:1, (60-67), Online publication date: 1-Dec-2006. Zhao H, Sapolsky R and Steinberg G (2006) Interrupting Reperfusion as a Stroke Therapy: Ischemic Postconditioning Reduces Infarct Size after Focal Ischemia in Rats, Journal of Cerebral Blood Flow & Metabolism, 10.1038/sj.jcbfm.9600348, 26:9, (1114-1121), Online publication date: 1-Sep-2006. Prosser-Loose E and Paterson P (2006) The FOOD Trial Collaboration: Nutritional Supplementation Strategies and Acute Stroke Outcome, Nutrition Reviews, 10.1111/j.1753-4887.2006.tb00212.x, 64:6, (289-294), Online publication date: 1-Jun-2006. Parsons M and Davis S (2006) Therapeutic Impact of MRI in Acute Stroke Magnetic Resonance Imaging in Ischemic Stroke, 10.1007/3-540-27738-2_3, (23-40), . Lumenta D, Plesnila N, Kläsner B, Baethmann A, Pruneau D, Schmid-Elsaesser R and Zausinger S (2006) Neuroprotective effects of a postischemic treatment with a bradykinin B2 receptor antagonist in a rat model of temporary focal cerebral ischemia, Brain Research, 10.1016/j.brainres.2005.11.043, 1069:1, (227-234), Online publication date: 1-Jan-2006. Bladin C and Davis S (2006) Acute Ischemic Stroke Handbook of Neuroemergency Clinical Trials, 10.1016/B978-012648082-5/50004-6, (1-16), . Adibhatla R and Hatcher J (2005) Cytidine 5?-Diphosphocholine (CDP-Choline) in Stroke and Other CNS Disorders, Neurochemical Research, 10.1007/s11064-004-9681-8, 30:1, (15-23), Online publication date: 1-Jan-2005. Bobyn P, Corbett D, Saucier D, Noyan-Ashraf M, Juurlink B and Paterson P (2005) Protein-energy malnutrition impairs functional outcome in global ischemia, Experimental Neurology, 10.1016/j.expneurol.2005.08.006, 196:2, (308-315), Online publication date: 1-Dec-2005. Galvão R, Diógenes J, Maia G, Filho E, Vasconcelos S, de Menezes D, Cunha G and Viana G (2005) Tenoxicam Exerts a Neuroprotective Action after Cerebral Ischemia in Rats, Neurochemical Research, 10.1007/s11064-004-9684-5, 30:1, (39-46), Online publication date: 1-Jan-2005. Gupta Y, Briyal S, Sharma U, Jagannathan N and Gulati A (2005) Effect of endothelin antagonist (TAK-044) on cerebral ischemic volume, oxidative stress markers and neurobehavioral parameters in the middle cerebral artery occlusion model of stroke in rats, Life Sciences, 10.1016/j.lfs.2004.11.025, 77:1, (15-27), Online publication date: 1-May-2005. Lippoldt A, Reichel A and Moenning U (2005) Progress in the Identification of Stroke-Related Genes, CNS Drugs, 10.2165/00023210-200519100-00002, 19:10, (821-832), . Uno M, Harada M, Takimoto O, Kitazato K, Suzue A, Yoneda K, Morita N, Itabe H and Nagahiro S (2013) Elevation of plasma oxidized LDL in acute stroke patients is associated with ischemic lesions depicted by DWI and predictive of infarct enlargement, Neurological Research, 10.1179/016164105X18395, 27:1, (94-102), Online publication date: 1-Jan-2005. Alexandrov A, Hall C, Labiche L, Wojner A and Grotta J (2004) Ischemic Stunning of the Brain, Stroke, 35:2, (449-452), Online publication date: 1-Feb-2004. Ohtake M, Morino S, Kaidoh T and Inoue T (2004) Three-dimensional structural changes in cerebral microvessels after transient focal cerebral ischemia in rats: Scanning electron microscopic study of corrosion casts, Neuropathology, 10.1111/j.1440-1789.2004.00560.x, 24:3, (219-227), Online publication date: 1-Sep-2004. Giffard C, Young A, Kerrouche N, Derlon J and Baron J (2016) Outcome of Acutely Ischemic Brain Tissue in Prolonged Middle Cerebral Artery Occlusion: A Serial Positron Emission Tomography Investigation in the Baboon, Journal of Cerebral Blood Flow & Metabolism, 10.1097/00004647-200405000-00003, 24:5, (495-508), Online publication date: 1-May-2004. Sharma S, Munusamy S, Thiyagarajan M and Kaul C Neuroprotective effect of peroxynitrite decomposition catalyst and poly(adenosine diphosphate—ribose) polymerase inhibitor alone and in combination in rats with focal ischemia, Journal of Neurosurgery, 10.3171/jns.2004.101.4.0669, 101:4, (669-675) Ritz M, Schmidt P and Mendelowitsch A (2004) Acute effects of 17β-estradiol on the extracellular concentration of excitatory amino acids and energy metabolites during transient cerebral ischemia in male rats, Brain Research, 10.1016/j.brainres.2004.07.004, 1022:1-2, (157-163), Online publication date: 1-Oct-2004. Wong G and Chung C (2017) Acute Ischaemic Stroke: Management, Recent Advances and Controversies, Hong Kong Journal of Emergency Medicine, 10.1177/102490790401100107, 11:1, (35-52), Online publication date: 1-Jan-2004. Duong T and Fisher M (2004) Applications of diffusion/perfusion magnetic resonance imaging in experimental and clinical aspects of stroke, Current Atherosclerosis Reports, 10.1007/s11883-004-0057-y, 6:4, (267-273), Online publication date: 1-Jul-2004. Weerd L, Thomas D, Thornton J and Lythgoe M (2004) MRI of Animal Models of Brain Disease Imaging in Biological Research, Part B, 10.1016/S0076-6879(04)86006-3, (149-177), . Allan S and Rothwell N (2003) Inflammation in central nervous system injury, Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences, 10.1098/rstb.2003.1358, 358:1438, (1669-1677), Online publication date: 29-Oct-2003. Wardlaw J, Murray V, Berge E, del Zoppo G and Wardlaw J (2009) Thrombolysis for acute ischaemic stroke Cochrane Database of Systematic Reviews, 10.1002/14651858.CD000213.pub2 Wardlaw J, Murray V, Berge E and del Zoppo G (2014) Thrombolysis for acute ischaemic stroke, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD000213.pub3 February 2003Vol 34, Issue 2 Advertisement Article InformationMetrics https://doi.org/10.1161/01.STR.0000054627.69159.C2PMID: 12574536 Manuscript receivedNovember 27, 2002Manuscript acceptedDecember 11, 2002Originally publishedFebruary 1, 2003 Keywordsthrombolysisacute stroke trialsstrokePDF download Advertisement